Detalhe da pesquisa
1.
Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial.
Respir Res
; 23(1): 375, 2022 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36566174
2.
Aged versus fresh autologous platelet transfusion in a two-hit healthy volunteer model of transfusion-related acute lung injury.
Transfusion
; 62(12): 2490-2501, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36300793
3.
EXpert consensus On Diaphragm UltraSonography in the critically ill (EXODUS): a Delphi consensus statement on the measurement of diaphragm ultrasound-derived parameters in a critical care setting.
Crit Care
; 26(1): 99, 2022 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35395861
4.
Ultrasound to Detect Central Venous Catheter Placement Associated Complications: A Multicenter Diagnostic Accuracy Study.
Anesthesiology
; 132(4): 781-794, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31977519
5.
Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients.
Eur Respir J
; 61(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36958745
6.
C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Differences Between PANAMO and FORCE Study.
Crit Care Med
; 51(11): e243-e244, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37902353
7.
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients.
Intensive Care Med Exp
; 11(1): 37, 2023 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37332066
8.
The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19.
Clin Transl Sci
; 15(4): 854-858, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029045
9.
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Respir Med
; 10(12): 1137-1146, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087611
10.
C5 inhibitors are not C5a inhibitors.
Expert Rev Anti Infect Ther
; 21(6): 685-686, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36989394
11.
Inhibiting C5 in patients with severe COVID-19-the incorrect target?
Lancet Respir Med
; 11(9): e80, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37307842
12.
Targeting C5a is beneficial in critically ill COVID-19 patients.
Immunobiology
; 228(6): 152743, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37717470
13.
Complement inhibition in severe COVID-19 - Blocking C5a seems to be key.
EClinicalMedicine
; 35: 100722, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33997737